BACH1 and melanoma: Importantly, the knockdown of BACH1 abolished the phenotypes elicited by PLK1 in both human and melanoma cells, with reduced glycolysis, increased OXPHOS, inhibited metastasis, and resensitization to Vemurafenib treatment.